Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Brepocitinib in Sarcoidosis. The expected timing is based on the latest available company guidance and may change.
2/10/25- To initiate Ph2 study in H2 2025; topline data in 2026. 02/06/26:- Positive Ph2 BEACON CS data; plan Ph3 initiation in 2026 after FDA engagement. 04/02/26:- Cutaneous sarcoidosis Ph3 initiation expected in H2 2026. 08/06/26:- BEACON+ Ph3 enrolled first patients in CS; topline data expected in 2028.
Verification
Confirm timing and program details against the company announcement or filing.